Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Heart Failure Drug Fails to Reduce Hospitalizations
Clinical Breakthroughs

New Heart Failure Drug Fails to Reduce Hospitalizations

By Will DossOct 10, 2019
Share
Facebook Twitter Email
Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor of Medicine in the Division of Cardiology, was a co-author of the study published in New England Journal of Medicine.

A new study published in New England Journal of Medicine found that an experimental drug did not lower hospitalization among patients suffering from heart failure with preserved ejection fraction, a common form of heart failure.

The study, based on a large clinical trial known as PARAGON, did suggest, however, that the drug may have some benefits particularly in women, a finding that merits further investigation, according to Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor of Medicine in the Division of Cardiology, a co-author of the study and a U.S. National Leader for the trial.

“PARAGON narrowly missed its primary endpoint but did appear to show a possible benefit in heart failure with preserved ejection fraction, particularly with regards to reducing heart failure hospitalizations and improving quality of life,” said Shah. “The data are not definitive, but it appears that women in particular benefit, and I am particularly intrigued by this finding.”

About half of heart failure cases are classified as reduced ejection fraction, meaning the heart is weak and unable to pump blood effectively. According to Shah, this type of heart failure is caused by direct damage to the heart, such as a heart attack, and is easily diagnosable and familiar to clinicians.

On the other hand, a heart with preserved ejection fraction (HFpEF) is pumping normally but the muscle is abnormally stiff, preventing the heart from filling properly. This type of heart failure, which appears to be associated with abnormalities in other organs in addition to the heart, is more difficult to diagnose using ultrasound, the usual method of diagnosing heart failure.

The proximate cause is often less clear, but cardiovascular risk factors like aging, obesity, a sedentary lifestyle, diabetes and high blood pressure appear to play a major role, according to Shah.

The current trial aimed to reduce the risk of hospitalization among patients aged 50 or older with symptoms of HFpEF. The investigators tested a novel treatment: a neprilysin inhibitor coupled with a blood pressure lowering drug, compared to a blood pressure lowering drug alone. Accordingly, about 2,400 patients received sacubitril–valsartan, while 2,400 patients received just valsartan.

After nearly three years, the trial showed that the new treatment narrowly missed statistical significance in reducing recurrent heart failure hospitalizations compared to valsartan alone.

However, Shah noted that examining different population’s responses to the drug suggested that women may respond better to the drug. Shah said he thought this may be linked to sacubitril, which increases natriuretic peptides, a hormone that helps the body combat heart failure.

“Women in particular have low natriuretic peptides and post-menopause are particularly vulnerable to natriuretic peptide deficiency,” Shah said. “The benefit seen in women in the PARAGON trial fits with our scientific knowledge of the natriuretic peptide pathway.”

In addition to the findings of the study, Shah noted that the size of the trial — over 4,800 patients — was an accomplishment. Prior to the establishment of the Northwestern HFpEF program in 2007, HFpEF-specific clinical care programs were few and far between, and enrolling patients in HFpEF clinical trials was very difficult, but the spread of similar programs around the world has made enrolling patients possible, Shah said.

“We developed a natural language processing algorithm that queried the electronic health record in order to improve efficiency in finding patients who were eligible for the PARAGON trial,” Shah said. “We were able to enroll the most patients of any other country, which shows that the U.S. can be a major participant in HFpEF trials.”

This clinical trial was supported by Novartis.

Cardiology Public Health Research
Share. Facebook Twitter Email

Related Posts

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

Comments are closed.

Latest News

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.